Papadopoulos I, Rudolph P, Wirth B, Weichert-Jacobsen K
Department of Urology, University of Kiel, Germany.
Urology. 1996 Aug;48(2):261-8. doi: 10.1016/S0090-4295(96)00169-0.
The biology of prostate cancer is poorly understood. Despite established prognostic criteria, a confident prediction of the clinical outcome is not always possible. Therefore, additional and more precise information is highly desirable. In the present study, we compared potential biologic markers with the laboratory, clinical, and histopathologic parameters of prostate-specific antigen (PSA) level, tumor stage, and tumor grade.
Paraffin-embedded material from 62 radical prostatectomies for prostate carcinoma was examined immunohistochemically using monoclonal antibody Ki-S5 to determine the tumor growth fraction and antibody DO-1 to assess p53 protein overexpression. Deoxyribonucleic acid-ploidy was analyzed by flow and image cytometry. Preoperative PSA levels were assessed by standard method. The tumors were categorized according to the Gleason grading system and staged postsurgery after the TNM classification.
The p53 expression, proliferation rate (Ki-S5), and rate of aneuploidy correlated closely with stage (P < 0.05) and Gleason score (P < 0.01). However, divergences were occasionally observed. The ploidy status correlated closely with proliferative activity and p53 expression. Conversely, no correlation was seen between these parameters and serum PSA content, the latter being significantly associated with the tumor stage alone.
The results characterize proliferation marker Ki-S5, p53 expression, and ploidy status as tumor biopotential markers, whereas PSA provides diagnostic information. Use of these investigative methods promises to provide additional information relevant in prognosis and therapy selection. Nonetheless, their precise prognostic value will have to be established in further studies.
前列腺癌的生物学特性尚未完全明确。尽管已有既定的预后标准，但对临床结局做出可靠预测并非总是可行。因此，非常需要更多且更精确的信息。在本研究中，我们将潜在的生物学标志物与前列腺特异性抗原（PSA）水平、肿瘤分期和肿瘤分级等实验室、临床及组织病理学参数进行了比较。
采用单克隆抗体Ki-S5通过免疫组织化学检查62例前列腺癌根治性前列腺切除术的石蜡包埋材料，以确定肿瘤生长分数，并用抗体DO-1评估p53蛋白过表达情况。通过流式细胞术和图像细胞术分析脱氧核糖核酸倍体。采用标准方法评估术前PSA水平。根据Gleason分级系统对肿瘤进行分类，并在术后按照TNM分类法进行分期。
p53表达、增殖率（Ki-S5）和非整倍体率与分期（P < 0.05）和Gleason评分（P < 0.01）密切相关。然而，偶尔也会观察到差异。倍体状态与增殖活性和p53表达密切相关。相反，这些参数与血清PSA含量之间未发现相关性，血清PSA含量仅与肿瘤分期显著相关。
结果表明增殖标志物Ki-S5、p53表达和倍体状态可作为肿瘤生物潜能标志物，而PSA提供诊断信息。使用这些研究方法有望提供与预后和治疗选择相关的额外信息。尽管如此，它们的确切预后价值仍需在进一步研究中确定。
